Alfa Chemistry Semiconductor: A Diverse Portfolio to Support Semiconductor Research

ZeOmega Adds Industry Leader to Management Team to Help Drive Payer and Provider Evolution into New Era of Value-based Care and Data-driven Quality and Experience

X-Therma Closes Oversubscribed $13M Series A Financing Led by LOREA AG

X-Therma closes an oversubscribed $13M Series A financing round led by LOREA AG. Funding will advance its breakthrough product platform rewriting biopreservation and cold chain.

Curebase Joins WCG Avoca Quality Consortium

Curebase Joins WCG Avoca Quality Consortium

Ribo-Seq Service Now Available on CD Genomics’s RNA Solutions Platforms

Epigenetics Data Analysis Service Now Available by CD Genomics’s Bioinformatics-Analysis Platform

Bioinformatics-analysis Platform is a leading open solution for data-driven innovation, which aims to discover the hidden potential in biological data and unearth new insights or predict new prospects related to life science research. CD Genomics has recently announced Epigenetics Data Analysis to move your disease research forward.

CD Genomics Fully Supports Your Microbiome Research with Comprehensive Sequencing Solutions

CD Formulation Optimizes Elemental Impurities Analysis Service

New scientific advisory Board at Qlucore

Qlucore, provider of intuitive bioinformatics software for research and precision and companion diagnostics, announces the creation of a Scientific Advisory Board (SAB), consisting of five members, chaired by Carl-Johan Ivarsson, CEO of Qlucore.

Emmes Acquires Institut Dr. Schauerte

WuXi STA Passes the First U.S. FDA Drug Product Pre-Approval Inspection at its Shanghai Waigaoqiao site

WuXi STA Forms Strategic Partnership with Coherent Biopharma

Sensyne Health and Cambridge University Hospitals NHS Foundation Trust Sign Strategic Research Agreement

Research will focus on CUH’s areas of disease expertise and specialism in cancer, cardiovascular disease and rare diseases New agreement covers 3 million patient records and brings the combined total of de-identified patient data directly accessible for medical research to 25.5 million patients

DFE Pharma researcher recognized as one of the 2021 Outstanding Early Career Scientists

Vyasa Joins NVIDIA Partner Network to Extend Availability of its GPU-Accelerated Applications Globally

Vyasa announced that it has joined the NVIDIA Partner Network (NPN) as a Solution Advisor (SA) – Consultant partner. Inclusion in the program enhances the availability of Vyasa’s deep learning applications to NVIDIA’s customers and partners.

Medinfar awarded first ever CPhI Verified Certificate

CPhI Verified certification improves supply chain transparency, providing a legal, regulatory and quality benchmark

Qlucore and Heidelberg University Hospital partnership receives 500,000 Euro from the EU for development of RNA-seq based cancer diagnostics

Qlucore is delighted to announce a joint project with Heidelberg University Hospital to develop Qlucore Diagnostics - a medical device artificial intelligence (AI) powered software for improved clinical diagnostics of lung cancer.

Curebase’s Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

Curebase’s Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

Caption Health Adds Virtual Health Exec to Board to Help Reshape Cardiac Ultrasound Market

Caption Health is announcing that Joe DeVivo, President of Hospitals and Health Systems at Teladoc Health, is joining its board of directors. Mr. DeVivo will share his expertise in Med Tech and Health Tech, gleaned over decades in the industry, to help guide the company on its mission to democratize access to high-quality ultrasounds.

RefleXion Receives Breakthrough Device Designation for Lung Cancer Treatment

RefleXion Medical, Inc., has been granted FDA Breakthrough Device Designation for its biology-guided radiotherapy (BgRT) for use in treating lung tumors. The breakthrough potential of BgRT lies in its ability to detect and then immediately treat multiple moving tumors. It is the first and only technology to use injected radiotracers to produce active signals, called emissions, from each tumor to guide treatment delivery.